Last reviewed · How we verify
DX-2930
DX-2930 is a Factor XIIa inhibitor that reduces contact pathway activation to prevent thrombosis without affecting primary hemostasis.
DX-2930 is a Factor XIIa inhibitor that reduces contact pathway activation to prevent thrombosis without affecting primary hemostasis. Used for Thrombotic disorders / thromboprophylaxis (Phase 3 development).
At a glance
| Generic name | DX-2930 |
|---|---|
| Sponsor | Shire |
| Drug class | Factor XIIa inhibitor |
| Target | Factor XIIa (FXIIa) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
DX-2930 selectively inhibits Factor XIIa (activated Factor XII), a key enzyme in the intrinsic coagulation pathway. By blocking this contact pathway component, the drug reduces pathological clot formation while preserving normal bleeding responses mediated by tissue factor pathway. This selective mechanism aims to provide antithrombotic benefit with reduced bleeding risk compared to conventional anticoagulants.
Approved indications
- Thrombotic disorders / thromboprophylaxis (Phase 3 development)
Common side effects
- Bleeding events
- Gastrointestinal adverse events
Key clinical trials
- A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia
- A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea
- A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries
- A Survey of Lanadelumab in Participants With Hereditary Angioedema
- A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
- Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease (PHASE2)
- A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
- A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DX-2930 CI brief — competitive landscape report
- DX-2930 updates RSS · CI watch RSS
- Shire portfolio CI